Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma
Anticancer agents that target both tumor cells and angiogenesis are of potential interest for glioblastoma (GB) therapy. One such agent is sorafenib (SFN), a tyrosine kinase inhibitor. However, poor aqueous solubility and undesirable side effects limit its clinical application, including local treat...
Main Authors: | Anne Clavreul, Emilie Roger, Milad Pourbaghi-Masouleh, Laurent Lemaire, Clément Tétaud, Philippe Menei |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2018.1507061 |
Similar Items
-
Development of lipid nanocapsules for antiangiogenic treatment of glioblastoma and evaluation of their potential for nose-to-brain drug delivery
by: Pourbaghi Masouleh, Milad
Published: (2018) -
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
by: Anne Clavreul, et al.
Published: (2017-09-01) -
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
by: Clavreul A, et al.
Published: (2019-04-01) -
Characterization of Different Functionalized Lipidic Nanocapsules as Potential Drug Carriers
by: José Manuel Peula-García, et al.
Published: (2012-02-01) -
Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy
by: Yunhui Jo, et al.
Published: (2018-11-01)